These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8683314)

  • 21. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.
    Kolesnikov-Gauthier H; Vanlemmens L; Baranzelli MC; Vennin P; Servent V; Fournier C; Carpentier P; Bonneterre J
    Breast Cancer Res Treat; 2012 Jan; 131(2):517-25. PubMed ID: 22037787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
    Crowe JP; Adler LP; Shenk RR; Sunshine J
    Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
    J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions.
    Walter C; Scheidhauer K; Scharl A; Goering UJ; Theissen P; Kugel H; Krahe T; Pietrzyk U
    Eur Radiol; 2003 Jul; 13(7):1651-6. PubMed ID: 12835981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
    Leboeuf R; Bénard F; Langlois MF
    Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
    Smith IC; Welch AE; Hutcheon AW; Miller ID; Payne S; Chilcott F; Waikar S; Whitaker T; Ah-See AK; Eremin O; Heys SD; Gilbert FJ; Sharp PF
    J Clin Oncol; 2000 Apr; 18(8):1676-88. PubMed ID: 10764428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
    van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
    J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
    Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
    Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
    Rousseau C; Devillers A; Sagan C; Ferrer L; Bridji B; Campion L; Ricaud M; Bourbouloux E; Doutriaux I; Clouet M; Berton-Rigaud D; Bouriel C; Delecroix V; Garin E; Rouquette S; Resche I; Kerbrat P; Chatal JF; Campone M
    J Clin Oncol; 2006 Dec; 24(34):5366-72. PubMed ID: 17088570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
    Hunter GJ; Choi NC; McLoud TC; Fischman AJ
    J Nucl Med; 1993 Sep; 34(9):1571-3. PubMed ID: 8394885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
    Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
    J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.
    Laubenbacher C; Saumweber D; Wagner-Manslau C; Kau RJ; Herz M; Avril N; Ziegler S; Kruschke C; Arnold W; Schwaiger M
    J Nucl Med; 1995 Oct; 36(10):1747-57. PubMed ID: 7562038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy.
    Nieweg OE; Wong WH; Singletary SE; Hortobagyi GN; Kim EE
    Ann N Y Acad Sci; 1993 Nov; 698():423-8. PubMed ID: 8279782
    [No Abstract]   [Full Text] [Related]  

  • 39. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.